Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash from Financing Activities (2016 - 2025)

Sunshine Biopharma filings provide 14 years of Cash from Financing Activities readings, the most recent being $724500.0 for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 55.23% to $724500.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $4.7 million, a 46.9% decrease, with the full-year FY2025 number at $4.7 million, down 46.9% from a year prior.
  • Cash from Financing Activities hit $724500.0 in Q4 2025 for Sunshine Biopharma, up from $75536.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $29.1 million in Q2 2022 to a low of -$2.1 million in Q4 2022.
  • Median Cash from Financing Activities over the past 5 years was $724500.0 (2025), compared with a mean of $3.1 million.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 8758.42% in 2022 and later skyrocketed 12730.71% in 2025.
  • Sunshine Biopharma's Cash from Financing Activities stood at -$23664.0 in 2021, then tumbled by 8758.42% to -$2.1 million in 2022, then skyrocketed by 98.54% to -$30519.0 in 2023, then skyrocketed by 5402.28% to $1.6 million in 2024, then plummeted by 55.23% to $724500.0 in 2025.
  • The last three reported values for Cash from Financing Activities were $724500.0 (Q4 2025), $75536.0 (Q3 2025), and $3.6 million (Q2 2025) per Business Quant data.